Skip to main content
SpringerLink
Log in

Neuron-specific enolase can be used as the sole guide to treat small-cell lung cancer patients in common clinical practice

  • Rapid Communication
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Summary

Serum samples were collected from 115 small-cell lung cancer patients before each course of chemotherapy and during follow-up. Levels of neuronspecific enolase (NSE) were measured and compared to the clinical assessments of the course of the disease, which were done by the responsible physician without knowledge of NSE-values. The predictive accuracy of an increase or decrease of NSE for a major response (CR+PR), SD or PD was 98%. Importantly no falsepositive rises of NSE were observed. On the basis of this large number of data it seems justified to conclude that in common clinical practice the treatment of small-cell lung cancer patients can be monitored by serial measurements of NSE alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Cooper EH, Splinter TAW, Brown DA, Muers MF, Peake MD, Pearson SC (1985) Evaluation of a radioimmunoassay for neuron-specific enolase in small cell lung cancer. Br J Cancer 52:333–338

    PubMed  Google Scholar 

  • Splinter TAW, Cooper EH, Kho GS, Oosterom R, Peake MD (1987) Neuron-specific enolase as a guide to the treatment of small cell lung cancer. Eur J Cancer Clin Oncol 23:171–176

    Article  PubMed  Google Scholar 

  • WHO Handbook for Reporting Results of Cancer Treatment (1979) WHO Offset Publication 48

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, University Hospital Dijkzigt, 3015 GD, Rotterdam, The Netherlands

    T. A. W. Splinter

  2. Department of Medical Oncology, Mater Miserecordia Hospital, Dublin, UK

    D. N. Carney & M. Teeling

  3. Pontefract General Infirmary, Pontefract, UK

    M. D. Peake

  4. Department of Pulmonology, University Hospital Dijkzigt, Rotterdam, The Netherlands

    G. S. Kho

  5. Department of Clinical Chemistry, Dr Daniël den Hoed Cancer Center, Rotterdam, The Netherlands

    R. Oosterom

  6. Unit for Cancer Research, University of Leeds, Leeds, UK

    E. H. Cooper

Authors
  1. T. A. W. Splinter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. N. Carney
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Teeling
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. D. Peake
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. S. Kho
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Oosterom
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. H. Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Splinter, T.A.W., Carney, D.N., Teeling, M. et al. Neuron-specific enolase can be used as the sole guide to treat small-cell lung cancer patients in common clinical practice. J Cancer Res Clin Oncol 115, 400–401 (1989). https://doi.org/10.1007/BF00400971

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00400971

Keywords

Search

Navigation